Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01688336 · ClinicalTrials.gov registry record · Phase 2
FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer
A Phase 2 study, sponsored by UNC Lineberger Comprehensive Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT01688336: Clinical Trial Phase 2 study, sponsored by UNC Lineberger Comprehensive Cancer Center.
NCT01688336 is a Phase 2 study that was terminated before completion, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 9 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01688336, a Phase 2 study, was terminated before completion, sponsored by UNC Lineberger Comprehensive Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
This single arm, multi-center phase II clinical trial will assess the safety and efficacy of FOLFIRINOX in the first-line setting in patients with unresectable locally advanced (ULA) and borderline resectable (BR) pancreatic cancer.
Primary Outcome
All patients who receive at least Day 1 of FOLFIRINOX treatment will be evaluable and followed up for up to 3 years for the primary outcome of overall survival (OS).
Interventions
- DRUG FOLFIRINOX
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2012-01 |
| Est. Completion | 2016-11-22 |
| Phase | Phase 2 |
Why NCT01688336 stopped before completion
NCT01688336 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which FOLFIRINOX is the first listed.
NCT01688336 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01688336 about?
NCT01688336 is a clinical study titled "FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer". This single arm, multi-center phase II clinical trial will assess the safety and efficacy of FOLFIRINOX in the first-line setting in patients with unresectable locally advanced (ULA) and borderline resectable (BR) pancreatic cancer.
What is the current status of trial NCT01688336?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2012-01. Estimated completion is 2016-11-22.
What interventions are being tested in trial NCT01688336?
The interventions under investigation include: FOLFIRINOX (DRUG).
Who is sponsoring clinical trial NCT01688336?
This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01688336's enrollment target sits among peer trials
9 1989th of 2000 higher than 11 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia